Clinical Trial Update: VX-950 and Peginterferon for Hepatitis C [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating VX-950 (telaprevir) in combination with Peginterferon for Hepatitis C has completed. The release does not provide trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon (Pegylated interferon)
• VX-950 (Telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED